Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Inhaled Nitric Oxide Market size was over USD 1.7 billion in 2024 and is estimated to reach USD 4.3 billion by the end of 2037, expanding at a CAGR of 8.1% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of inhaled nitric oxide is assessed at USD 1.8 billion.
Persistent pulmonary hypertension (PPHN), which is a severe condition elevated due to vascular resistance is one of the primary indications that is positively impacting the inhaled nitric oxide market. As per the 2025 Cleveland Clinic Organization report, 7% to 10% of newborns with PPHN expires, and for those who survive, 25% experience long-term effects owing to the limited flow of oxygen to the brain. Oscillation ventilation, nasal cannula, and continuous positive air pressure (CPAP) are a few therapies to combat this condition, as stated by the 2025 Nationwide Children’s Hospital Organization.
Moreover, the adoption of oral treatments for various disorders constitutes an optimistic impact on the evolution of the inhaled nitric oxide market. For example, soluble guanylate cyclase stimulators enhance the sGC enzyme interaction with nitric oxide to allow blood vessel relaxation in the lungs, according to the 2020 Pulmonary Hypertension Association Organization. Additionally, endothelin receptor antagonists, phosphodiesterase inhibitors, endothelin receptor antagonists, prostacyclin analogue, and selective IP receptor agonists are a variety of treatment-based therapies that are contributing to the market growth.
Inhaled Nitric Oxide Sector: Growth Drivers and Challenges
Growth Drivers
- Increase in preterm childbirth: As per the International Federation of Gynecology and Obstetrics 2024 report, over 13.0 million babies are born prematurely every year, accounting for over 10% of the total live births globally. This kind of labor usually takes place exactly before 37 weeks of pregnancy due to factors including social characteristics, medical conditions, and behavioral characteristics. Thereby, smoking and drug avoidance, prenatal care, and special medical attention are precautions to follow during unexpected childbirth, as prescribed by the U.S. Centers for Disease Control and Prevention 2024, which in turn are effectively boosting the inhaled nitric oxide market.
- High prevalence of lung disorders: Globally 7.0 million deaths take place due to lung cancer and chronic obstructive pulmonary disease (COPD) as stated by the Global Initiative for Asthma Organization 2025. However, the Global Initiative for COPD 2024 guide stated that almost 40.0% of COPD cases are caused due to tobacco intake, which can be cured by adopting smoking cessation. This technique poses the ability to heighten the quitting rates from 14% to 27% with the provision of effective resources and time. Healthcare providers provide anti-smoking interventions and encourage patients to quit, hence amplifying the inhaled nitric oxide market.
Challenges
- Rising economic burden of treatments: Approximately, 90% of the total health expenditure of America, USD 4.5 trillion, accounts for chronic and mental illness, as reported by the CDC government, in July 2024. Besides, annually over 944,800 of the population die due to cardiac arrest, constituting more than 1 in 3 deaths. This created a toll on the economy, accounting for USD 254 billion in health costs every year. Additionally, care costs for rare diseases account for USD 240 billion, USD 413 billion, USD 173 billion, USD 300 billion, USD 360 billion, USD 13.4 billion, and USD 46 billion respectively. This is a restraint for the inhaled nitric oxide market development.
Medical cost per risk type
|
Risks |
Cost per year |
|
Cancer |
USD 240 billion |
|
Physical inactivity |
USD 117 billion |
|
Excessive liquor consumption |
USD 249 billion |
Source: CDC 2024
- Limitation in sufficient supply: Disruption in the supply of nitric oxide gas is a major challenge, obstructing the growth of the inhaled nitric oxide market globally. It usually undergoes complicated chemical reactions for the manufacturing process, hence not easily accessible in huge quantities. In addition, specific knowledge of infrastructure is necessary to ensure the high purity of the gas during the production process which limits the availability. Moreover, the confined scalability of nitric oxide-based therapy results in price variation, especially in locations with huge demand and insufficient supply framework.
Inhaled Nitric Oxide Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.1% |
|
Base Year Market Size (2024) |
USD 1.7 billion |
|
Forecast Year Market Size (2037) |
USD 4.3 billion |
|
Regional Scope |
|
Inhaled Nitric Oxide Segmentation
Product Type (Inhaled Nitric Oxide Delivery Systems, Consumables)
In inhaled nitric oxide market, inhaled nitric oxide delivery systems segment is projected to dominate revenue share of over 44.8% by 2037. These systems are commercially available and use pressurized cylinders to regulate the absorptions of nitric oxide and nitrogen dioxide delivery. Contributions made by global organizations through financial subsidies and accelerated approvals are remarkably driving market expansion. For instance, in October 2024, Mallinckrodt plc received the U.S. Food and Drug Administration (FDA) clearance for INOmax EVOLVE DS delivery system for inhalation purposes, comprising an integrated design for nitric oxide distribution.
Application (Neonatal Respiratory Treatment, Chronic Obstructive Pulmonary Disease, Acute Respiratory Disease Syndrome, Tuberculosis Treatment, Malaria Treatment)
The neonatal respiratory treatment segment is expected to influence the inhaled nitric oxide market at a considerable rate by the end of 2037. Factors such as the rise in birth rates and enhanced awareness about the available options are boosting the market demand subsequently. As per the Our World in Data Organization report, the world population was 8.2 billion in 2024, among which 132.0 million were newborn babies, majorly susceptible to lung disabilities. To overcome this, the July 2023 NLM report suggested adopting mechanical ventilation as a respiratory therapy, which reduces morbidity between 18 to 22 months of age by incorporating both invasive and non-invasive approaches.
Our in-depth analysis of the global inhaled nitric oxide market includes the following segments:
|
Product Type |
|
|
Application |
|
|
Strength |
|
|
End user |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportInhaled Nitric Oxide Industry - Regional Synopsis
North America Market Analysis
North America in inhaled nitric oxide market is predicted to capture over 42.6% revenue share by 2037. Factors such as the government strategies for fund provision, and intense research and development are driving the demand in the region. For instance, in February 2021, the Cystic Fibrosis Foundation acknowledged an investment of USD 2.17 million to Beyond Air to develop a portable inhaled nitric oxide treatment to fight nontuberculous mycobacteria (NTM). Therefore, such contributions by authoritative organizations are enhancing the demand for inhaled nitric oxide in the region.
The U.S. inhaled nitric oxide market is growing due to the rapid development of advanced healthcare facilities across the nation. In July 2022, Massachusetts General Hospital conducted a mass general-led study on 70 pregnant women, wherein it was identified that the latest treatment procedure for pneumonia combined with a high dosage of inhaled nitric oxide gas is an effective therapy. Additionally, researchers from Boston hospitals stated that the insertion of the gas twice daily among 20 women reduced the rate of respiratory issues without causing any side effects. Thereby, effective cooperation from multiple health facilities and expert case studies are driving the increased need for nitric oxide.
The inhaled nitric oxide market in Canada is witnessing significant growth since evaluation activities and clinical trials are extremely prevalent. In February 2023, the Canadian Pediatric Society specified the level of initiation to be 20 ppm for infants and highlighted that the calculated clinical response to be less than 30 minutes. It further marked the maximum level up to 40 ppm in cases of absent clinical response. In case of unforeseen birth, the dose ranges were allocated between 5 ppm to 10 ppm, which can be extended to 20 ppm. In addition, the nitrogen dioxide concentration was mandated to be below 0.5 ppm to maintain the mixture quantity, thus denoting the need for the market to boost.
APAC Market Statistics
The APAC inhaled nitric oxide market is projected to be the fastest-growing landscape due to the increased focus on health accessibility and quality. According to the retrospective propensity-matched study conducted by NLM in October 2024, out of 2,767 patients from different regions, 1,879 suffered from breathing, and 888 were part of the intubated group. Out of the lot, there were patients from Asia and it was found that 3.9% of patients did not use nitric oxide, whereas 7.2% implemented it. The result indicated improvement in oxygenation indices for the dose intake, paving the way for market upliftment.
The inhaled nitric oxide market in India is expecting substantial growth since it has been considered a vital therapy to provide remedies to patients with breathing disabilities. As per the Global Asthma Network study conducted by NLM in May 2022, the overall burden of asthma in the country was 34.3 million, constituting 13.0% of the global patient population. In addition, 13.2 per million deaths took place due to the disorder, accounting for 27.9% of disability-adjusted life years (DALYs) in the population. Therefore, inhaled nitric oxide as a treatment is in huge demand to combat asthma.
The inhaled nitric oxide market in China is gaining traction due to the presence of regulatory support to develop innovative treatment procedures. The NLM in its May 2023 report specified that the fractional concentration of nasal NO (FnNO) test is convenient to quantity the nitric oxide production by sinuses and nasal cavity, denoting a standard diagnosis of sinusitis, rhinitis, and assessment of disease brutality. Also, the Chinese guidelines for the diagnosis and treatment of allergic rhinitis endorsed FnNO. Hence, the supportive regulations and governing bodies of the country are driving the market growth.
Companies Dominating the Inhaled Nitric Oxide Landscape
- Linde PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- SOL Group
- Air Liquide S.A.
- Vero Biotech LLC
- Bellerophon Therapeutics Inc.
- Merck KGaA
- GE Healthcare
- Messer Group
- Nu-Med Plus Inc.
- Beyond Air Inc.
Companies dominating the oxide market are rapidly gaining exposure due to the importance of its production for overall health maintenance and the efficient flow of oxygen, nutrients, and blood to body parts. Additionally, several organizational bodies have made approvals of products and services for this purpose. For instance, in January 2025, Beyond Air, Inc. gained the market authorization of the LungFit PH from the Australian Therapeutic Goods Administration (TGA). The product is not accessible for sale as a Class IIb medical device to dispatch nitric oxide, hence an effective contribution towards the market upliftment. Such key players are:
In the News
- In May 2024, Connecticut Children's and UConn Health launched the latest Primary Ciliary Dyskinesia (PCD) Center to diagnose and medicate both children and adults with rare genetic disorders by utilizing a nasal nitric oxide machine sponsored by the Walden W. & Jean Young Shaw Foundation.
- In January 2023, VERO Biotech Inc., announced an investment of USD 30.0 million in collaboration with Petrichor for the commercialization and future development of GENOSYL Delivery System which is a tankless inhaled nitric oxide system.
Author Credits: Rajrani Baghel
- Report ID: 7163
- Published Date: Feb 18, 2025
- Report Format: PDF, PPT
